Literature DB >> 6725522

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.

S J Santner, P D Feil, R J Santen.   

Abstract

Estrone and estradiol concentrations in breast tumor tissue are an order of magnitude higher than circulating plasma levels in postmenopausal women with breast cancer. Local production of estrogen in the neoplastic tissue is one of several possible explanations for this plasma/tissue gradient. This study evaluated breast tumor estrogen production via the estrone sulfate to estrone (sulfatase) pathway and compared this with the androstenedione to estrone (aromatase) system in human and rodent mammary tumors. Estrogen production from estrone sulfate was related linearly with time and tissue concentrations, exhibited an apparent Km of 20 microM, and produced a linear Eadie-Hofstee kinetic plot consistent with a single class of enzymatic sites. Measurement of sulfatase in 35 human breast tumors using enzyme saturating conditions revealed estrone production ranging from 0.8-125 mumol/g protein . h. The corresponding range in host mammary tumors was 3.5-7.1 mumol/g protein . h. In human breast tumors, sulfatase activity did not correlate with the levels of estrogen receptor or progesterone receptor. Comparison of sulfatase with aromatase activity in human tumors at physiological levels of substrate revealed estrone formation via sulfatase of 2.8 pmol estrone produced/g protein . h, while aromatase produced only 0.27 pmol/g protein . h. In rat mammary tumors, sulfatase activity was similar to that in human tumors, whereas aromatase activity could not be detected, even with a highly sensitive assay. Thus, estrone sulfatase appears to be the enzyme primarily responsible for intratissue estrone production in hormone-dependent breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725522     DOI: 10.1210/jcem-59-1-29

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  54 in total

1.  Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.

Authors:  P E Lønning; M Dowsett; A Jones; D Ekse; S Jacobs; F McNeil; D C Johannessen; T J Powles
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Estrogen metabolism as a regulator of estrogen action in the mammary gland.

Authors:  M Miettinen; V Isomaa; H Peltoketo; D Ghosh; P Vihko
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

3.  Aromatase immunoreactivity is increased in mammographically dense regions of the breast.

Authors:  Celine M Vachon; Hironobu Sasano; Karthik Ghosh; Kathleen R Brandt; David A Watson; Carol Reynolds; Wilma L Lingle; Paul E Goss; Rong Li; Sarah E Aiyar; Christopher G Scott; V Shane Pankratz; Richard J Santen; James N Ingle
Journal:  Breast Cancer Res Treat       Date:  2010-06-05       Impact factor: 4.872

Review 4.  Molecular therapy of breast cancer: progress and future directions.

Authors:  Sheng-Xiang Lin; Jiong Chen; Mausumi Mazumdar; Donald Poirier; Cheng Wang; Arezki Azzi; Ming Zhou
Journal:  Nat Rev Endocrinol       Date:  2010-07-20       Impact factor: 43.330

Review 5.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

6.  Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.

Authors:  Daphne Gschwantler-Kaulich; Anneliese Fink-Retter; Klaus Czerwenka; Gernot Hudelist; Axel Kaulich; Ernst Kubista; Christian F Singer
Journal:  Tumour Biol       Date:  2010-12-29

7.  Oestrone sulphate, adipose tissue, and breast cancer.

Authors:  R A Hawkins; M L Thomson; E Killen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

8.  Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).

Authors:  B L Nguyen; G Chetrite; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 9.  A review of coumarin derivatives in pharmacotherapy of breast cancer.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.